CVE:SBM

Sirona Biochem Competitors

C$0.39

+0.05 (+13.04 %)

(As of 04/20/2021 12:10 PM ET)

Add

Compare

Today's Range

C$0.31

Now: C$0.39▼

C$0.39

50-Day Range

C$0.33

MA: C$0.41▼

C$0.56

52-Week Range

C$0.19

Now: C$0.39▼

C$0.56

Volume88,315 shs

Average Volume135,487 shs

Market CapitalizationC$88.79 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Sirona Biochem (CVE:SBM) Vs. IMV, RVX, FRX, ATE, ONC, and IPA

Should you be buying SBM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Sirona Biochem, including IMV (IMV), Resverlogix (RVX), Fennec Pharmaceuticals (FRX), Antibe Therapeutics (ATE), Oncolytics Biotech (ONC), and ImmunoPrecise Antibodies (IPA).

Sirona Biochem vs. IMV Stock

Sirona Biochem (CVE:SBM) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Sirona Biochem and IMV's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sirona Biochem	N/A	N/A	N/A
IMV	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sirona Biochem and IMV, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sirona Biochem	0	0	0	0	N/A
IMV	0	4	0	0	2.00

IMV has a consensus price target of C$5.08, suggesting a potential upside of 49.51%. Given IMV's higher probable upside, analysts clearly believe IMV is more favorable than Sirona Biochem.

Valuation & Earnings

This table compares Sirona Biochem and IMV's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sirona Biochem	C$123,870.00	716.78	C$-2,959,580.00	C($0.01)	-30.00
IMV	C$3,000.00	76,739.13	C$-39,136,958.00	C($0.58)	-5.88

Sirona Biochem has higher revenue and earnings than IMV. Sirona Biochem is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Sirona Biochem vs. Resverlogix Stock

Sirona Biochem (CVE:SBM) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Sirona Biochem and Resverlogix's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sirona Biochem	N/A	N/A	N/A
Resverlogix	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sirona Biochem and Resverlogix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sirona Biochem	0	0	0	0	N/A
Resverlogix	0	0	0	0	N/A

Valuation & Earnings

This table compares Sirona Biochem and Resverlogix's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sirona Biochem	C$123,870.00	716.78	C$-2,959,580.00	C($0.01)	-30.00
Resverlogix	N/A	N/A	N/A	C$0.01	63.57

Resverlogix has lower revenue, but higher earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Summary

Resverlogix beats Sirona Biochem on 2 of the 3 factors compared between the two stocks.

Sirona Biochem vs. Fennec Pharmaceuticals Stock

Sirona Biochem (CVE:SBM) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sirona Biochem	N/A	N/A	N/A
Fennec Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and Fennec Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sirona Biochem	0	0	0	0	N/A
Fennec Pharmaceuticals	0	0	2	0	3.00

Valuation and Earnings

This table compares Sirona Biochem and Fennec Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sirona Biochem	C$123,870.00	716.78	C$-2,959,580.00	C($0.01)	-30.00
Fennec Pharmaceuticals	C$170,000.00	1,153.31	C$-24,858,868.00	C($0.96)	-7.89

Sirona Biochem has higher earnings, but lower revenue than Fennec Pharmaceuticals. Sirona Biochem is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Fennec Pharmaceuticals beats Sirona Biochem on 4 of the 6 factors compared between the two stocks.

Sirona Biochem vs. Antibe Therapeutics Stock

Sirona Biochem (CVE:SBM) and Antibe Therapeutics (TSE:ATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and Antibe Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sirona Biochem	N/A	N/A	N/A
Antibe Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and Antibe Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sirona Biochem	0	0	0	0	N/A
Antibe Therapeutics	0	0	2	0	3.00

Antibe Therapeutics has a consensus price target of C$7.75, suggesting a potential upside of 79.40%. Given Antibe Therapeutics' higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Sirona Biochem.

Valuation and Earnings

This table compares Sirona Biochem and Antibe Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sirona Biochem	C$123,870.00	716.78	C$-2,959,580.00	C($0.01)	-30.00
Antibe Therapeutics	C$9.33 million	21.07	C$-35,814,009.00	C($0.79)	-5.49

Sirona Biochem has higher earnings, but lower revenue than Antibe Therapeutics. Sirona Biochem is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats Sirona Biochem on 4 of the 7 factors compared between the two stocks.

Sirona Biochem vs. Oncolytics Biotech Stock

Sirona Biochem (CVE:SBM) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and Oncolytics Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sirona Biochem	N/A	N/A	N/A
Oncolytics Biotech	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and Oncolytics Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sirona Biochem	0	0	0	0	N/A
Oncolytics Biotech	0	1	2	0	2.67

Oncolytics Biotech has a consensus price target of C$6.00, suggesting a potential upside of 64.38%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Sirona Biochem.

Valuation and Earnings

This table compares Sirona Biochem and Oncolytics Biotech's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sirona Biochem	C$123,870.00	716.78	C$-2,959,580.00	C($0.01)	-30.00
Oncolytics Biotech	N/A	N/A	N/A	C($0.56)	-6.52

Oncolytics Biotech has lower revenue, but higher earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Oncolytics Biotech beats Sirona Biochem on 3 of the 5 factors compared between the two stocks.

Sirona Biochem vs. ImmunoPrecise Antibodies Stock

Sirona Biochem (CVE:SBM) and ImmunoPrecise Antibodies (CVE:IPA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Sirona Biochem and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sirona Biochem	N/A	N/A	N/A
ImmunoPrecise Antibodies	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sirona Biochem and ImmunoPrecise Antibodies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sirona Biochem	0	0	0	0	N/A
ImmunoPrecise Antibodies	0	0	0	0	N/A

Valuation and Earnings

This table compares Sirona Biochem and ImmunoPrecise Antibodies' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sirona Biochem	C$123,870.00	716.78	C$-2,959,580.00	C($0.01)	-30.00
ImmunoPrecise Antibodies	C$17.18 million	13.08	C$-4,082,906.00	C($0.21)	-55.05

Sirona Biochem has higher earnings, but lower revenue than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Sirona Biochem, indicating that it is currently the more affordable of the two stocks.

Summary

Sirona Biochem beats ImmunoPrecise Antibodies on 4 of the 5 factors compared between the two stocks.